These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36282213)

  • 21. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis.
    Yau K; Chan CT; Abe KT; Jiang Y; Atiquzzaman M; Mullin SI; Shadowitz E; Liu L; Kostadinovic E; Sukovic T; Gonzalez A; McGrath-Chong ME; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Levin A; Blake PG; Colwill K; Gingras AC; Hladunewich MA
    CMAJ; 2022 Feb; 194(8):E297-E305. PubMed ID: 35115375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.
    Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A
    Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients.
    Aoun M; Kahwaji RM; Sleilaty G; Boueri C; Hawi J; Khalil CB; Hage V
    Adv Clin Exp Med; 2022 Aug; 31(8):855-861. PubMed ID: 35438849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
    Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
    Front Immunol; 2022; 13():816220. PubMed ID: 35145522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
    Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.
    Kaplonek P; Cizmeci D; Fischinger S; Collier AR; Suscovich T; Linde C; Broge T; Mann C; Amanat F; Dayal D; Rhee J; de St Aubin M; Nilles EJ; Musk ER; Menon AS; Saphire EO; Krammer F; Lauffenburger DA; Barouch DH; Alter G
    Sci Transl Med; 2022 May; 14(645):eabm2311. PubMed ID: 35348368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.
    Grunau B; Golding L; Prusinkiewicz MA; Asamoah-Boaheng M; Armour R; Marquez AC; Jassem AN; Barakauskas V; O'Brien SF; Drews SJ; Haig S; Lavoie PM; Goldfarb DM
    Microbiol Spectr; 2022 Apr; 10(2):e0270221. PubMed ID: 35254166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.
    La Verde N; Riva A; Cona MS; Gabrieli A; Cattaneo M; Fasola C; Lipari G; De Stradis C; Favorito V; Lombardi Stocchetti B; Chizzoniti D; Covizzi A; Rulli E; Galli F; Ruggieri L; Gambaro A; Ferrario S; Dalu D; Tarkowski MS
    Int J Cancer; 2023 Feb; 152(4):661-671. PubMed ID: 36056571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.